LOS ANGELES, Oct. 25, 2016 /CNW/ -- In a new research
study being presented tomorrow at the CHEST 2016 annual meeting,
ResMed (NYSE: RMD) will share evidence that people who use a
self-management app when treating their sleep apnea with positive
airway pressure (PAP) are significantly more likely to stick with
their therapy.
The observational study included more than 128,000 people with
sleep apnea whose devices allow for their therapy to be remotely
monitored by their clinician or by the patients themselves via
myAir™, ResMed's cognitive behavior–based patient engagement app
for the web and iPhone®.
More than 87 percent of PAP users were compliant on therapy when
using ResMed's myAir and monitored by AirView™, compared to 70
percent compliance for those monitored by AirView alone (a 24%
relative increase). While continuous positive airway pressure
(CPAP) therapy, the gold standard in treating sleep apnea, has
vastly improved due to innovations in device comfort and ease of
use, in general, CPAP adherence may still be as low as 50 percent
without the use of wireless monitoring.
"This new study shows that online self-monitoring tools engage
patients and significantly improve their compliance and adherence
to treatment," said ResMed Medical Director Adam Benjafield, PhD. "While our study focused
on PAP users, we believe these results may be generalized more
broadly in terms of the role online tools can have in improving
medical treatment compliance overall."
"Half of all patients don't take their medications as
prescribed,2 and we know that same statistic holds true
for compliance with PAP therapy for sleep apnea," said Benjafield.
"The effects of poor treatment adherence are profound, not only for
the number of people suffering due to poor medication adherence,
but also in terms of emergency room visits, hospitalizations and
their financial burden to the healthcare system."
About myAir
myAir is available on the web and via an
iPhone app to patients using ResMed's Air10™ devices. myAir allows
people to track the progress of their therapy between visits to
their clinician, including a simple daily sleep score, details on
four key treatment metrics and personalized coaching tips.
As a companion to AirView, ResMed's cloud-based tool for
healthcare professionals, myAir reinforces the efforts of
clinicians and helps patients keep themselves informed and
motivated, factors long considered to play a role in effective
treatment of sleep apnea and other medical conditions.
Clinicians view myAir as a powerful tool for reducing the risks
and costs associated with these health problems for their sleep
apnea patients. Every day, 1,000 new patients sign up for
myAir.
"Our patients engage with their therapy so much more after
joining myAir, since it's easy to use and understand the data,"
said John Quinlan, owner of
Quinlan's Pharmacy and Medical Equipment in Upstate New York. "When
more engagement leads to better compliance, I think equipment
providers everywhere should encourage their patients to use tools
like myAir."
Study details
This retrospective, observational study
was designed to minimize risks of potential bias due to differences
between the myAir and AirView-only groups that affect outcome
variables by matching patients on propensity score. There were
128,037 patients in the study cohort. Patients in both groups were
effectively treated with PAP therapy over the 90 days.
There was a significant improvement in the percent of patients
that reached Medicare adherence within 90 days (87.3% for myAir
patients vs. 70.4% for AirView-only patients, with a p value less
than 0.0001), showing an absolute 16.9% improvement (a relative 24%
improvement) in adherence. Additionally mean daily PAP usage was
also significantly higher in myAir patients compared to
AirView-only (5.9 hours vs. 4.9 hours, respectively).
The study will be presented on October
26, 2016, at the CHEST Annual Meeting in Los Angeles. Visit ResMed Booth #2411.
About ResMed
ResMed (NYSE:RMD) changes lives with
award-winning medical devices and cutting-edge cloud-based software
applications that better diagnose, treat and manage sleep apnea,
chronic obstructive pulmonary disease (COPD) and other chronic
diseases. ResMed is a global leader in connected care, with more
than 2 million patients remotely monitored every day. Our
5,000-strong team is committed to creating the world's best
tech-driven medical device company – improving quality of life,
reducing the impact of chronic disease, and saving healthcare costs
in more than 100 countries.
ResMed.com | Facebook | Twitter | LinkedIn
1 NEHI. "Thinking Outside the Pillbox." 2009
2 Osterberg L and Blaschke T. N Engl J Med 2005
* myAir's iPhone app is available in the U.S. The web application
is available in 21 countries.
** CPAP compliance, as defined by the U.S. Center for Medicare
& Medicaid Services, requires using CPAP 4 hours a night for
70% of nights in a 30-day span within the first 90 days of
therapy.
For
Media:
|
For
Investors:
|
Jayme
Rubenstein
|
Agnes Lee
|
Public Relations
Manager
|
Senior Director,
Investor Relations
|
O:
858-836-6798
|
O:
858-836-5971
|
news@resmed.com
|
investorrelations@resmed.com
|
Photo - http://photos.prnewswire.com/prnh/20161024/432019-INFO
Logo - http://photos.prnewswire.com/prnh/20140310/LA79234LOGO-a
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/results-from-worlds-largest-study-on-sleep-apnea-and-digital-connected-care-300350272.html
SOURCE ResMed Inc.